1820679-70-6

Basic information

• Product Name: (-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate
• CAS NO: 1820679-70-6
• Molecular Weight: 236.262
• Mol File: 1820679-70-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate(1820679-70-6)
• EPA Substance Registry System: (-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate(1820679-70-6)

Safety Data

• Hazardous Substances Data: 1820679-70-6(Hazardous Substances Data)

Usage

General Description

(-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate is a chiral compound with potential applications in the pharmaceutical industry. It is a derivative of piperidine with a tert-butyl group and two fluorine atoms attached to the piperidine ring. The presence of the amino and carboxylate groups suggests that this compound may be involved in biochemical processes such as enzyme inhibition or receptor binding. The chiral nature of this compound, denoted by the (-)-(S*) configuration, indicates that it has different stereochemical properties than its enantiomer, which may be important for its biological activity. The tert-butyl group also contributes to the compound's stability and lipophilic properties, which could be advantageous in drug design and delivery. Overall, (-)-(S*)-tertbutyl 4-amino-3,3-difluoropiperidine-1-carboxylate is a potentially important compound for the development of new pharmaceutical agents.

Upstream product

• 1893408-11-1 (S)-tert-butyl 3,3-difluoro-4-hydroxypiperidine-1-carboxylate 
• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 
• 1067914-81-1 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol 
• 1067915-34-7 ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate 
• 851314-55-1 ethyl N-[3-(ethyloxy)-2,2-difluoro-3-oxopropyl]-N-(phenylmethyl)-beta-alaninate 
• 1215071-17-2 tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate 
• 1209780-71-1 tert-butyl 3,3-difluoro-4-hydroxy-piperidine-1-carboxylate 
• 1239596-54-3 3,3-difluoropiperidin-4-ol 
• 1239596-53-2 N-benzyl-3,3-difluoro-4-hydroxypiperidine 
• 1067914-82-2 (±)-tert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate 

Relevant articles and documents

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.